Dynavax Technolo Stock Price, News & Analysis

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has announced its participation in two major upcoming investor conferences:

• TD Cowen 45th Annual Healthcare Conference on March 4 at 1:10 p.m. ET
• Barclays 27th Annual Global Healthcare Conference on March 11 at 10:00 a.m. ET

The company will provide webcasted presentations accessible through their investor relations website. Dynavax currently markets two commercial products: HEPLISAV-B vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18+, and CpG 1018 adjuvant, used in HEPLISAV-B and various COVID-19 vaccines.

Dynavax Technologies (DVAX) reported strong financial results for Q4 and full year 2024, with HEPLISAV-B net product revenue growing 26% year-over-year to $268.4 million. The company's Q4 revenue reached $71.1 million, up 39% from the previous year.

Key highlights include:

• HEPLISAV-B U.S. market share increased to 44% by end of 2024
• Full year 2024 GAAP net income of $27.3 million ($0.21 per share)
• Cash position of $713.8 million as of December 31, 2024
• Adjusted EBITDA of $51.9 million for 2024, up 329% year-over-year

For 2025, Dynavax expects HEPLISAV-B net product revenue between $305-325 million and adjusted EBITDA of at least $75 million. The company plans to complete its $200 million share repurchase program and anticipates top-line results from its Phase 1/2 shingles vaccine trial in Q3 2025.

Dynavax Technologies (DVAX) has responded to Deep Track Capital's nomination of four board candidates, highlighting its strong execution and value creation strategy. The company reported record HEPLISAV-B revenue in 2024 with 26% year-over-year growth and expects to achieve 60% market share by 2030.

The company maintains a strong financial position with $714 million in cash as of year-end 2024 and has implemented a $200 million share repurchase plan, with $100 million already executed through an accelerated program. Dynavax recently secured a $30 million contract with the U.S. Department of Defense for its plague vaccine program and is advancing its shingles vaccine program.

The board has initiated refreshment changes, including appointing two new independent directors and planning board declassification. Despite multiple settlement attempts with Deep Track, negotiations have been unsuccessful, with Deep Track seeking board control without paying a control premium.

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on vaccine development, has scheduled its fourth quarter and full year 2024 financial results announcement for February 20, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.

Dynavax currently markets two commercial products: HEPLISAV-B vaccine, approved in the U.S., EU, and Great Britain for hepatitis B virus prevention in adults 18 and older, and CpG 1018 adjuvant, used in HEPLISAV-B and various COVID-19 vaccines.

Dynavax Technologies (DVAX) announced significant board changes as part of its ongoing refreshment program. Emilio Emini, Ph.D. and Lauren Silvernail will join the Board effective February 3, 2025. Two current directors, Peggy Phillips and Julie Eastland, will step down at the 2025 Annual Meeting.

The company plans to seek stockholder approval for Board declassification at the 2025 Annual Meeting. If approved, directors will transition to one-year terms starting from the 2026 Annual Meeting, with all directors standing for annual election by 2028.

The company reported strong performance, achieving record annual revenue for HEPLISAV-B in 2024 and maintaining an active $200 million share repurchase program. Following the 2025 Annual Meeting, the Board will consist of nine directors, with six of its eight independent directors appointed since 2020.

Dynavax Technologies (DVAX) reported preliminary unaudited financial highlights for Q4 and full year 2024. HEPLISAV-B achieved record annual revenue of $268 million, representing 26% growth year-over-year, and Q4 revenue of $71 million, up 39% from Q4 2023.

The company expects the U.S. hepatitis B adult vaccine market to reach over $900 million in annual sales by 2030, with HEPLISAV-B targeting at least 60% market share. The company completed enrollment in its Phase 1/2 shingles vaccine trial, with top-line results expected in Q3 2025. Additionally, Dynavax secured a new $30 million contract with the U.S. Department of Defense for plague vaccine development.

As of December 31, 2024, the company reported approximately $714 million in cash, cash equivalents, and marketable securities.

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has announced its upcoming participation at the 7th Annual Evercore HealthCONx Conference. The presentation is scheduled for Tuesday, December 3 at 2:35 p.m. ET.

Interested parties can access the webcast through the 'Events & Presentations' section on the company's investor relations website at investors.dynavax.com/events-presentations.

Dynavax Technologies has announced a $100 million Accelerated Share Repurchase (ASR) program under an agreement with Goldman Sachs & Co. . This ASR is part of a $200 million share repurchase program authorized by Dynavax's Board of Directors in November 2024. Upon completion, $100 million will remain in the program.

Dynavax will initially receive approximately 6.1 million shares, representing around 80% of the $100 million paid, based on the $13.01 closing stock price on November 8, 2021. The final number of shares repurchased will be determined by the volume-weighted average prices during the ASR term, with final settlement expected in Q1 2025. As of November 5, 2024, Dynavax had about 131.5 million shares outstanding.

Chief Financial Officer Kelly MacDonald stated that the ASR reflects confidence in Dynavax's business and commitment to shareholder value through strategic capital allocation.

Dynavax (DVAX) reported strong Q3 2024 financial results, with HEPLISAV-B achieving record quarterly net product revenue of $79.3 million, up 27% year-over-year. The company's total revenues reached $80.6 million, a 16% increase from Q3 2023. HEPLISAV-B's U.S. market share grew to 44%, with particularly strong performance in retail pharmacy (55%) and IDN segments (56%). The company expects the hepatitis B adult vaccine market to reach over $900 million by 2030, with HEPLISAV-B targeting at least 60% market share. Dynavax reported net income of $17.6 million and maintains a strong cash position of $764 million. The company also announced a $200 million share repurchase program and discontinued its Tdap-1018 development program.